SLU-PP-332 dosing & administration
A groundbreaking exercise mimetic compound that tricks your body into thinking it's training for a marathon—boosting metabolism, burning fat, and building endurance without you ever having to hit the gym.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Timing
Best time to take
Morning dosing aligns with your body's natural metabolic rhythm. If taking before exercise, dose 30-60 minutes prior for optimal effect. Can also split doses between morning and early afternoon.
With food?
Can be taken with or without food. Some users prefer taking with a light meal to minimize any potential gastrointestinal discomfort.
If stacking
If combining with other metabolic compounds, space them out and start each one separately to identify individual effects. Some users stack with L-Carnitine for enhanced fat oxidation support.
Adjusting your dose
Increase if
- You've used the starting dose for 2+ weeks with no issues
- You're not noticing expected metabolic improvements
- Your body weight and composition goals aren't progressing
Decrease if
- You experience persistent GI discomfort
- Energy levels become erratic or you feel overstimulated
- Any unexpected side effects arise
- Sleep quality deteriorates
Signs of right dose
- Improved exercise endurance and recovery
- Gradual fat loss with maintained muscle
- Stable energy throughout the day
- Better overall metabolic markers if tested
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (just under the skin) or oral administration (published mouse studies used intraperitoneal injection)
Best sites
Storage
Before reconstitution
Store powder or tablets at room temperature (59-77°F / 15-25°C) in a cool, dry place away from direct sunlight. Refrigeration extends shelf life. Keep in original sealed container with desiccant if provided.
After reconstitution
If using injectable form, refrigerate at 36-46°F (2-8°C). Never freeze. Keep away from light. Oral forms should remain at room temperature in original packaging.
Signs of degradation — discard the vial
Sample daily schedule
Morning (6-9 AM)
250-500 mcg injection
Site: Oral or subcutaneous (belly area)
Morning dosing aligns with natural cortisol rhythm and metabolic activation. If exercising, take 30-60 minutes before for potential synergistic effects.
Early afternoon (12-2 PM, if splitting dose)
250-500 mcg injection
Site: Oral or rotate injection site
Second dose can help maintain consistent blood levels. Avoid dosing late in the day to prevent any potential impact on sleep.
Safety
Is it safe?
Side effects
Commonly reported: Mild GI discomfort, Increased energy, Mild warmth or temperature increase
Less common: Changes in appetite, Mild headache
Stop and seek help if
- Any signs of allergic reaction—stop immediately
- Persistent GI issues that don't improve with dose adjustment
- Significant changes in heart rate or blood pressure
- Sleep problems that persist beyond the first week
- Any side effect that feels concerning or unusual
- Your research protocol or cycle is complete
SLU-PP-332 is a research compound, not an FDA-approved medication. Never start, stop, or change your dosing without guidance from a qualified healthcare provider. This information is for educational purposes only—not medical advice.
Flagged pairings
- Semaglutide — Use caution—both affect metabolism and glucose. Combining may lead to excessive metabolic effects. Consult a physician.
- Diabetes medications (metformin, insulin) — May compound glucose-lowering effects. Risk of hypoglycemia. Requires physician supervision and possible dose adjustment.
- Thyroid medications (levothyroxine) — Both affect metabolism. Combination may cause excessive metabolic stimulation. Consult endocrinologist.
Published research
What the studies show
Billon C, Sitaula S, Banerjee S, et al. · 2023
This foundational study showed that SLU-PP-332 increases mitochondrial function and cellular respiration in muscle cells. When given to mice, it boosted oxidative muscle fibers and enhanced exercise endurance—essentially mimicking the effects of training without the actual workout.
Billon C, Schoepke E, Avdagic A, et al. · 2024
Mice with diet-induced obesity or genetic obesity showed impressive results: SLU-PP-332 increased energy expenditure, boosted fat burning, reduced fat mass, and improved insulin sensitivity. Importantly, these effects happened without reducing appetite or food intake.
Billon C, Appourchaux K, Côté I, et al. · 2025
This study introduced an improved version (SLU-PP-915) that works when taken orally. It enhanced exercise performance and synergized with actual exercise training—meaning the compound and physical training together produced better results than either alone.
Losby M, Hayes M, Valfort A, et al. · 2024
ERR activation (the mechanism SLU-PP-332 uses) was found to regulate autophagy—the cellular cleanup process. This suggests additional anti-aging and cellular health benefits beyond just metabolic enhancement.
Okda HE, Zhao P, Hayes M, Duvall C, et al. · 2026
Medicinal-chemistry study of SLU-PP-332 analogues (Int J Biol Macromol 2026; full text PMC13112601). Measured SLU-PP-332's kinetic solubility at 0.2 μM in pH 7.4 phosphate-buffered saline, which the authors describe as extremely low and consistent with its high cLogP (4.05); several analogues kept comparable ERR activation with improved solubility or metabolic stability.
Xu W, Billon C, Li H, Wilderman A, et al. · 2024
Mouse pressure-overload heart failure study (Circulation 2024; full text PMC10842599). SLU-PP-332 improved ejection fraction, reduced fibrosis and increased survival without affecting cardiac hypertrophy. Methods: the powder was dissolved in DMSO as a stock, then diluted to 5 mg/mL in 12% DMSO and 15% Cremophor in PBS and given by intraperitoneal injection at 25 mg/kg twice daily.
Head to head
SLU-PP-332 compared
Want the full picture?
The complete SLU-PP-332 research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.